38 results about "Tetrahydrobiopterin" patented technology

The invention describes the use of a PDE4 inhibitor in combination with BH4 or a BH4 derivative for the prevention and / or treatment of respiratory diseases.

Disclosed is a composition that includes a tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with phenylketonuria that includes administering, to the patient, a composition that contains tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with ADHD that includes administering a tetrahydropterin to the patient. Compositions for the treatment of ADHD are also described.

The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.

The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.

Recombinant microbial cells and methods for producing 5HTP, melatonin and related compounds using such cells are described. More specifically, the recombinant microbial cell may comprise exogenous genes encoding one or more of an L-tryptophan hydroxylase, a 5-hydroxy-L-tryptophan decarboxylyase, a serotonin acetyltransferase, an acetylserotonin O-methyltransferase; and means for providing tetrahydrobiopterin (THB), and can be further genetically modified to enrich one or more of tryptophan, S-adenosyl-L-methinonine and acetyl coenzyme A. Related sequences and vectors for use in preparing such recombinant microbial cells are also described.

The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.

The present invention discloses methods of treating diabetic gastroparesis by administering tetrahydrobiopterin or a derivative thereof.

L-citrulline for treatment of endothelial dysfunction and in particular of erectile dysfunction and a pharmaceutical composition comprising L-citrulline in combination with one or more substances selected from the group consisting of pycnogenol, aqueous extract of Viscum album, NADPH, tetrahydrobiopterin, folic acid and mixtures thereof.

Disclosed are a core-shell structural anode catalyst for direct borohydride fuel cells and a preparation method thereof. The catalyst comprises Mcore-Aushell nano composite particles which utilize M as the core and utilizes Au as the shell, and the particle size of the Mcore-Aushell particles ranges from 10nm to 50nm. The preparation method includes steps: firstly, adding M-salt and a stabilizing agent into a solvent sequentially, introducing nitrogen gas into the solvent and then stirring and heating the solvent, introducing and stirring nitrogen gas again, dropping a reducing agent to realize reaction and obtain M-nano catalyst sol, and then obtaining M-nano particles after filtering and washing; secondly, dissolving the M-nano particles into solvent, adding stabilizing agent and introducing nitrogen gas into the solvent along with stirring, adding chloroauric acid-tetrahydrofuran solution, introducing nitrogen gas again, dropping reducing agent to realize reaction and prepare nano-catalyst sol, separating and washing the nano-catalyst sol, drying the nano-catalyst sol in vacuum, and finally preparing powdered Mcore-Aushell nano-particle catalyst by means of grinding. The core-shell structural anode catalyst for direct borohydride fuel cells has higher BH4 (tetrahydrobiopterin)-oxidation activity and is low in hydrogen evolution, and accordingly fuel utilization rate is improved.

The invention belongs to medical biology technology, and relates to an organ preservation solution and its preparation. According to the preparation steps per 1000ml, it comprises: taking 1.57mg of tetrahydrobiopterin and 6.92mg of diazoxide and dissolving them in 1ml of dimethyl sulfoxide As a mother liquor; prepare 0.1mol / L CaCl210ml for later use; add 800ml double distilled water into a 1000ml container, add KCl 1.12g, MgCl22.64g, mannitol 10.93g, histidine 4.63g, glutathione 0.92g, Sodium glutamate 3.74g, stir until clear; add sodium lactate 6.90ml, stir until clear; add 0.1mol / L CaCl22.5ml, stir until clear; add stock solution and mother liquor, stir until clear. The pH was adjusted to 7.3-7.5, the osmotic pressure was adjusted to 320Osm / L, and the volume was adjusted to 1000ml with double distilled water. Store at 4°C for low temperature storage.

The present invention relates to proteins with pteridine glycosyltransferase activity and an analysis method using the same. Since the proteins glycate tetrahydrobiopterin selectively through an enzyme reaction, the method enables quantitative analysis of tetrahydrobiopterin and oxides thereof at the same time or quantitative analysis of tetrabiopterin selectively.